CNS trials are uniquely challenging due to the complexity and variability of disorders, symptoms, and disease progression. Assessing CNS-related symptoms relies on subjective, non-linear ratings, making endpoint collection more intricate than in other therapeutic areas.

Clinical trial leaders need to prioritize scientific expertise when choosing an eCOA vendor as many existing eCOA technologies lack the robust features and rater-friendly design needed for accurate CNS assessments and fail to support end-to-end trial execution, ultimately impacting data quality.